Pakistan-China Health Deals Worth $629.5m Signal Pharma Push
Pakistan’s healthcare and pharmaceutical sector received a major investment boost after Federal Health Minister Syed Mustafa Kamal said more than 20 commercial agreements worth about $629.5 million had been signed following a Pakistan-China healthcare investment conference in Islamabad. The announcement was made on Wednesday as the government sought to present the health sector as a serious destination for foreign investment and industrial expansion.
The agreements were linked to the Pakistan-China Pharmaceutical and Healthcare B2B Investment Conference held in Islamabad on July 17 and 18. According to the minister, the deals cover multiple high-value areas, including vaccine production, active pharmaceutical ingredients, medical devices, clinical trials and other pharmaceutical segments that are central to strengthening Pakistan’s health manufacturing base.
Kamal said 22 companies had signed investment agreements during the two-day engagement, describing the development as an important step for the country’s health economy. He also stated that 84 memorandums of understanding, estimated at nearly $800 million, were signed at the conference and could later develop into formal investment commitments if negotiations proceed successfully.
Speaking at a press conference in Islamabad, the health minister framed the outcome as a national achievement and said the government wanted to move beyond symbolic paperwork. He indicated that the priority was to convert business interest into binding commercial arrangements capable of bringing investment, technology transfer, industrial growth and employment opportunities.
The conference brought together a large number of delegates from both countries, with hundreds of representatives from Chinese and Pakistani pharmaceutical companies participating in business-to-business meetings. Officials described the gathering as one of the largest Pakistan-China engagements dedicated specifically to the pharmaceutical and healthcare industry.
A key part of the government’s strategy is local vaccine production. Kamal said Pakistan had developed and approved a National Local Vaccine Production Policy for the first time, creating a formal framework to support domestic vaccine manufacturing and reduce the country’s dependence on imported vaccines.
Pakistan currently uses 13 vaccines under its national immunisation programme, and all of them are imported. The new policy is aimed at improving health security by encouraging local production capacity, reducing import exposure and ensuring more reliable access to essential vaccines during emergencies or global supply disruptions.
The minister also highlighted Pakistan’s dependence on imported active pharmaceutical ingredients despite strong local medicine production. While the country manufactures a large share of its finished medicines domestically, most of the raw ingredients used in those medicines still come from abroad, making the sector vulnerable to currency pressure, supply chain shocks and international price fluctuations.
The newly announced agreements include projects in API manufacturing, vaccine production, clinical trials, generic injectable formulations and medical devices. If implemented effectively, these investments could help Pakistan upgrade its pharmaceutical value chain, expand exports and create specialised jobs in research, regulation, production and healthcare technology.
The next challenge will be execution. Pakistan will need regulatory clarity, reliable infrastructure, transparent approvals and sustained investor confidence to turn the announced deals into working factories, laboratories and export-ready products. If the agreements progress as planned, they could mark an important shift from import dependence toward stronger health-sector self-reliance and deeper industrial cooperation with China.